BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31809565)

  • 1. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT
    Ezban M; Hansen M; Kjalke M
    Haemophilia; 2020 Jan; 26(1):156-163. PubMed ID: 31809565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
    Pickering W; Hansen M; Kjalke M; Ezban M
    J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
    Tiefenbacher S; Clausen WHO; Hansen M; Lützhøft R; Ezban M
    Haemophilia; 2019 Sep; 25(5):893-901. PubMed ID: 31294905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring factor VIII activity in samples from patients treated with N8-GP (Esperoct
    Møss J; Clausen WHO; Ezban M
    Haemophilia; 2021 May; 27(3):e389-e392. PubMed ID: 33314455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.
    Hegemann I; Koch K; Clausen WHO; Ezban M; Brand-Staufer B
    Acta Haematol; 2020; 143(5):504-508. PubMed ID: 31639805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reagent-specific underestimation of turoctocog alfa pegol (N8-GP) clotting activity owing to decelerated activation by thrombin.
    Persson E; Foscolo T; Hansen M
    Res Pract Thromb Haemost; 2019 Jan; 3(1):114-120. PubMed ID: 30656284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
    Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
    Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct
    Bjørnsdottir I; Støvring B; Søeborg T; Jacobsen H; Sternebring O
    Drugs R D; 2020 Jun; 20(2):75-82. PubMed ID: 32152818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
    Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
    Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study.
    Church N; Leong L; Katterle Y; Ulbrich HF; Noerenberg I; Kitchen S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):823-832. PubMed ID: 29984531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [